Crystalys Therapeutics Launches with $205M Series A Financing to Transform the Treatment of Gout

Crystalys Therapeutics Inc., ('Crystalys' or 'the Company'), a clinical-stage biopharmaceutical company, is announcing its launch with a $205 million Series A financing to support its mission of addressing the significant unmet medical needs of people living with gout. read more →